OncoMed Pharmaceuticals is a biotechnology company dedicated to improving cancer treatment by creating novel medicines that address the fundamental biologic pathways critical to tumor initiation, growth, metastases and recurrence. We are leveraging our understanding of cancer stem cell pathways and immuno-oncology targets to discover and develop novel therapeutics that could provide important alternatives for the treatment of cancer. OncoMed currently has seven internally discovered drug candidates in clinical development, as well as several active research programs undergoing preclinical evaluation. To support the advancement of our clinical-stage candidates and our continued discovery efforts, OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline. Since our founding in August 2004, we have raised more than $600 million, more than half of which has come from collaboration funding from our pharmaceutical partnerships.